2586 days ago
Shares in Amryt Pharma (AMYT) are starting to move the right way and ever faster;as clear progress is made with its portfolio. On Tuesday we had the, not unexpected, news that it has started the phase 3 ( that is to say final human) trials of AP101, its lead drug candidate, a potential treatment for Epidermolysis Bullosa (EB). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin
